The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the Medical Research Council (MRC).
“The Deep and Frequent Phenotyping study will recruit 250 volunteers from existing study cohorts led by the Dementias Platform UK”.
The ultimate aim is to improve the success rate of clinical trials for treatments in Alzheimer’s Disease – many of which have failed – probably due to the interventions under investigation starting a too late a phase in disease progression, after irreparable damage has taken place.
The biomarkers and tests under investigation will include:
- Monitoring alterations in movement and walking (“gait”) assessments, using wearable devices.
- Ophthalmological assessments of the retina.
- Magnetic Resonance Imaging (MRI) brain scans.
- Magnetoencephalography (MEG) to measure the magnetic fields produced by nerve cells.
- Electroencephalogram (EEG) brain scans to measure electrical currents associated with brain activity.
- Positron emission tomography (PET) brain scans, to detect build-up of rogue proteins or other changes associated with Alzheimer’s Disease.
- Thinking and memory (cognitive) assessments, to measure the ability of participants to pay attention, solve problems and remember.
- Clinical assessments, including blood and urine samples and cerebrospinal fluid (CSF).
World’s most in depth study to detect early signs of Alzheimer’s Disease. London [Online]: Medical Research Council (MRC), August 22nd 2016.